Is Hims The Next Big Name In Peptides? Shares Recover From Earnings Dive.

Hims stock inched lower Tuesday, recovering from a late-Monday dive, as the telehealth giant seemingly moves closer to the peptide segment. Hims & Hers Health (HIMS) is expected to be a key beneficiary after the Food and Drug Administration's advisors last month recommended the agency allow compounding pharmacies to make six previously banned peptides. These chains of amino acids naturally…